Navigation Links
Nektar Announces Retirement of Irwin Lerner from Board of Directors
Date:1/29/2009

SAN CARLOS, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that Irwin Lerner has retired from its Board of Directors effective January 23, 2009. Mr. Lerner, former Chairman of Hoffmann-La Roche Inc., has been a member of the Nektar Board of Directors since 1999. He is retiring due to personal reasons.

The Board of Directors and the Company wish to acknowledge the contributions that Mr. Lerner has made by providing the benefit of his extensive industry experience to Nektar over a near ten-year period.

"It is a privilege to have worked with Irwin as a colleague and advisor," said Howard W. Robin, President and CEO of Nektar and member of the Board of Directors. "On behalf of the entire Board and the Company, we extend our deepest appreciation to Irwin for his many years of service to Nektar."

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. More information on Nektar is available at http://www.nektar.com

     Jennifer Ruddock, 650-631-4954
     jruddock@nektar.com

     Susan A. Noonan, 212-966-3650
     The SAN Group
     Susan@sanoonan.com

'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
2. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
3. Nektar Therapeutics to Webcast R&D Day on November 12th
4. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
5. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
6. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
7. Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets
8. Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
9. Nektars PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
10. Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
11. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
(Date:3/23/2017)... 2017 According to a report by Transparency ... fragmented due to the presence of a large pool of participants; ... Fisher , and Sigma-Aldrich, compete with each other in this market. ... more than 76% of this market in 2016.  ... As of now, a large number ...
(Date:3/23/2017)... March 23, 2017 In today,s ... equities in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: ... (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market ... free report at: ...
(Date:3/22/2017)... N.Y. , March 22, 2017 Regeneron Pharmaceuticals, ... the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to ... the U.K. Biobank resource. The initiative will enable researchers to ... new medicines for a wide range of serious and life ... ...
Breaking Biology Technology:
(Date:3/22/2017)... , March 21, 2017 Vigilant ... company serving law enforcement agencies, announced today the appointment ... as director of public safety business development. ... law enforcement experience, including a focus on the aviation ... his most recent position, Mr. Sheridan served as the ...
(Date:3/20/2017)... ALLENTOWN, Pa. , March 20, 2017 ... PD 2.0 personal spirometer and Wellness Management System (WMS), ... Founded in 2010, PMD Healthcare is a ... Company with a mission dedicated to creating innovative solutions ... of life. With that intent focus, PMD developed the ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... Matching enables to match face pictures against each other or against large databases. ... Systems) ... the fastest software for biometric Face Matching on the market. The speed is ...
Breaking Biology News(10 mins):